| POTĚŠIL, David, Stanislav STEJSKAL, Marek BORSKÝ, Pavel ŠIMARA, Martina HAVELKOVÁ, Filip RÁZGA, Irena KRONTORÁD KOUTNÁ, Dana DVOŘÁKOVÁ, Jiří MAYER, Zdeněk RÁČIL and Zbyněk ZDRÁHAL. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. Analytical Letters. PHILADELPHIA: TAYLOR & FRANCIS INC, 2014, vol. 47, No 6, p. 944-957. ISSN 0003-2719. Available from: https://dx.doi.org/10.1080/00032719.2013.860538. |
Other formats:
BibTeX
LaTeX
RIS
@article{1184645,
author = {Potěšil, David and Stejskal, Stanislav and Borský, Marek and Šimara, Pavel and Havelková, Martina and Rázga, Filip and Krontorád Koutná, Irena and Dvořáková, Dana and Mayer, Jiří and Ráčil, Zdeněk and Zdráhal, Zbyněk},
article_location = {PHILADELPHIA},
article_number = {6},
doi = {http://dx.doi.org/10.1080/00032719.2013.860538},
keywords = {Mass spectrometry; Flow cytometry; Cell isolation technique; Chronic myelogenous leukemia; Imatinib; Peripheral blood},
language = {eng},
issn = {0003-2719},
journal = {Analytical Letters},
title = {Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry},
url = {http://www.tandfonline.com/doi/full/10.1080/00032719.2013.860538},
volume = {47},
year = {2014}
}
TY - JOUR
ID - 1184645
AU - Potěšil, David - Stejskal, Stanislav - Borský, Marek - Šimara, Pavel - Havelková, Martina - Rázga, Filip - Krontorád Koutná, Irena - Dvořáková, Dana - Mayer, Jiří - Ráčil, Zdeněk - Zdráhal, Zbyněk
PY - 2014
TI - Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry
JF - Analytical Letters
VL - 47
IS - 6
SP - 944-957
EP - 944-957
PB - TAYLOR & FRANCIS INC
SN - 00032719
KW - Mass spectrometry
KW - Flow cytometry
KW - Cell isolation technique
KW - Chronic myelogenous leukemia
KW - Imatinib
KW - Peripheral blood
UR - http://www.tandfonline.com/doi/full/10.1080/00032719.2013.860538
N2 - Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distribution within the studied system (e.g., peripheral blood) may be of high importance for understanding the principles of drug action and possible patient resistance to treatment. Intracellular or more precisely cell-associated, imatinib concentrations in patients, were shown to be higher compared to those in plasma, but still only limited data related to the methodology aspects of cell-associated concentrations are available. Herein is presented an assessment of the cell-associated imatinib determination assay by mass spectrometry. Three approaches were evaluated to isolate cells from the peripheral blood of chronic myelogenous leukemia patients. Erythrocyte lysis was found to cause substantial leakage of cell-associated imatinib in the first step. Selected alternative procedures utilizing density gradients did not affect the cell-associated imatinib concentration significantly. Cell isolates were subjected to flow cytometry which revealed differences in the population composition of peripheral blood cell isolates among individual patients indicating that the cell isolate composition should be addressed with the cell-associated imatinib concentration. The proposed approach may be utilized for the determination of intracellular concentration of imatinib and for other drugs in which the intracellular concentration plays a key role in the therapy.
ER -
POTĚŠIL, David, Stanislav STEJSKAL, Marek BORSKÝ, Pavel ŠIMARA, Martina HAVELKOVÁ, Filip RÁZGA, Irena KRONTORÁD KOUTNÁ, Dana DVOŘÁKOVÁ, Jiří MAYER, Zdeněk RÁČIL and Zbyněk ZDRÁHAL. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. \textit{Analytical Letters}. PHILADELPHIA: TAYLOR \&{} FRANCIS INC, 2014, vol.~47, No~6, p.~944-957. ISSN~0003-2719. Available from: https://dx.doi.org/10.1080/00032719.2013.860538.
|
